D
Diane Prager
Researcher at University of California, Los Angeles
Publications - 56
Citations - 9154
Diane Prager is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Receptor & Transactivation. The author has an hindex of 31, co-authored 56 publications receiving 8981 citations. Previous affiliations of Diane Prager include Charles University in Prague & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Thomas J. Lynch,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +15 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +14 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy as mentioned in this paper.
Journal ArticleDOI
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Roy S. Herbst,Diane Prager,Robert C. Hermann,Lou Fehrenbacher,Bruce E. Johnson,Alan B. Sandler,Mark G. Kris,Hai T. Tran,Pam Klein,Xin Li,D. Ramies,David H. Johnson,Vincent A. Miller +12 more
TL;DR: Erlotinib with concurrent carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC did not confer a survival advantage over carboplatins and pac litaxels alone, and never smokers treated with erlot inib and chemotherapy seemed to experience an improvement in survival.
Journal ArticleDOI
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V. Heymach,Bruce E. Johnson,Diane Prager,Edit Csada,Jaromír Roubec,Miloš Pešek,Irena Spasova,Chandra P. Belani,Istvan Bodrogi,Shirish Gadgeel,Sarah J. Kennedy,Jeannie Hou,Roy S. Herbst +12 more
TL;DR: In this paper, the authors evaluated the activity of vandetanib plus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC).
Journal ArticleDOI
Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant.
TL;DR: 952STOP behaves as a dominant negative inhibitor of endogenous IGF-I receptor function, probably by assembling nonfunctional hybrid rat/mutant human receptor tetramers in Rat-1 fibroblasts.